{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:47:10Z","timestamp":1792504030499,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cld.2026.01.009","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:57:13Z","timestamp":1773320233000},"page":"483-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic Dysfunction-Associated Steatohepatitis in the Middle East: Clinical Challenges and Strategies to Bridge the Gap"],"prefix":"10.1016","volume":"30","author":[{"given":"Saleh A.","family":"Alqahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin V.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Abaalkhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cld.2026.01.009_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2026.01.009_bib2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/liv.15852","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa","volume":"44","author":"Younossi","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2026.01.009_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13448","article-title":"Prevalence, risk factors, and interventions for obesity in Saudi Arabia: a systematic review","author":"Salem","year":"2022","journal-title":"Obes Rev"},{"issue":"4","key":"10.1016\/j.cld.2026.01.009_bib4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s12072-021-10215-5","article-title":"The clinical and economic burden of non-alcoholic steatohepatitis in the Middle East: behind the scene","volume":"15","author":"Mak","year":"2021","journal-title":"Hepatol Int"},{"issue":"6","key":"10.1016\/j.cld.2026.01.009_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4103\/sjg.sjg_314_22","article-title":"The NAFLD-MAFLD debate through the lens of the Arab world","volume":"28","author":"Tharwat","year":"2022","journal-title":"Saudi J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2026.01.009_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4103\/sjg.sjg_122_24","article-title":"Stigma in steatotic liver disease: a survey of patients from Saudi Arabia","volume":"30","author":"Alqahtani","year":"2024","journal-title":"Saudi J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2026.01.009_bib7","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2026.01.009_bib8","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.jhep.2023.08.012","article-title":"Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: one size fits all this time","volume":"80","author":"El-Kassas","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.009_bib9","article-title":"Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: a modified Delphi-based adaptation of international standards","author":"Abaalkhail","year":"2025","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.cld.2026.01.009_bib10","article-title":"Worldwide burden of liver cancer due to metabolic dysfunction-associated steatohepatitis from 1990 to 2019: insights from the Global Burden of Disease study","volume":"14","author":"Huang","year":"2024","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.cld.2026.01.009_bib11","doi-asserted-by":"crossref","DOI":"10.2174\/1573399820666230731105704","article-title":"Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus in the MENA region: a systematic review","volume":"20","author":"Khalil","year":"2024","journal-title":"Curr Diabetes Rev"},{"issue":"7","key":"10.1016\/j.cld.2026.01.009_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271108","article-title":"The future health and economic burden of obesity-attributable type 2 diabetes and liver disease among the working-age population in Saudi Arabia","volume":"17","author":"Coker","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cld.2026.01.009_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12876-021-01828-z","article-title":"Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease","volume":"21","author":"Alqahtani","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cld.2026.01.009_bib14","doi-asserted-by":"crossref","unstructured":"Alqahtani SA, AlMuhaidib S, Raptis DA, et al. SLM 2024 \u2013 4: Trends in Adult Liver Transplantation Indications and Survival Rates in Saudi Arabia: Metabolic Dysfunction-Associated Steatohepatitis as the Leading Indication (2011\u20132023). In: Proceedings of the Saudi Association for the Study of Liver Diseases and Transplantation - Saudi Liver Meeting, Riyadh, Saudi Arabia. Saudi J Gastroenterol. 2024;30(Supp 2):pS50. doi: 10.4103\/sjg.sjg_439_24","DOI":"10.4103\/sjg.sjg_439_24"},{"issue":"4","key":"10.1016\/j.cld.2026.01.009_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4103\/sjg.SJG_122_18","article-title":"Nonalcoholic fatty liver disease burden - saudi Arabia and United Arab Emirates, 2017-2030","volume":"24","author":"Alswat","year":"2018","journal-title":"Saudi J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2026.01.009_bib16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4103\/sjg.sjg_62_24","article-title":"The burden of metabolic dysfunction-associated steatotic liver disease and viral hepatitis in Saudi Arabia","volume":"30","author":"Alqahtani","year":"2024","journal-title":"Saudi J Gastroenterol"},{"issue":"S1","key":"10.1016\/j.cld.2026.01.009_bib17","first-page":"S1156","volume":"82","author":"Alqahtani","year":"2025","journal-title":"Hepatology"},{"issue":"1089","key":"10.1016\/j.cld.2026.01.009_bib18","article-title":"Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging","volume":"91","author":"Zhang","year":"2018","journal-title":"Br J Radiol"},{"issue":"2","key":"10.1016\/j.cld.2026.01.009_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","article-title":"Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease","volume":"79","author":"Kjaergaard","year":"2023","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2026.01.009_bib20","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","article-title":"Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.cld.2026.01.009_bib21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2026.01.009_bib22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/sjg.sjg_576_21","article-title":"Saudi association for the study of liver diseases and transplantation position statement on the hepatology workforce in Saudi Arabia","volume":"28","author":"Al-Judaibi","year":"2022","journal-title":"Saudi J Gastroenterol"},{"issue":"25","key":"10.1016\/j.cld.2026.01.009_bib23","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.3748\/wjg.v26.i25.3528","article-title":"Management of nonalcoholic fatty liver disease in the Middle East","volume":"26","author":"Sanai","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2026.01.009_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/16549716.2023.2194715","article-title":"Public policies to increase physical activity and reduce sedentary behavior: a narrative synthesis of \u201creviews of reviews\u201d","volume":"16","author":"Alghannam","year":"2023","journal-title":"Glob Health Action"},{"issue":"4","key":"10.1016\/j.cld.2026.01.009_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0297278","article-title":"Health and economic burden of insufficient physical activity in Saudi Arabia","volume":"19","author":"Alqahtani","year":"2024","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cld.2026.01.009_bib29","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3390\/nu17071257","article-title":"The impact of dietary interventions on metabolic outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) and comorbid conditions, including obesity and type 2 diabetes","volume":"17","author":"Jurek","year":"2025","journal-title":"Nutrients"},{"issue":"S1","key":"10.1016\/j.cld.2026.01.009_bib30","first-page":"S912","volume":"78","author":"Garcia-Larsen","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2026.01.009_bib31","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/nbu.12707","article-title":"Mediterranean diet for the management of metabolic dysfunction-associated steatotic liver disease in non-Mediterranean, Western countries: what's known and what\u2019s needed?","volume":"49","author":"Sualeheen","year":"2024","journal-title":"Nutr Bull"},{"issue":"1","key":"10.1016\/j.cld.2026.01.009_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-089793","article-title":"Prevention of type 2 diabetes mellitus among people with Middle Eastern backgrounds living in high-income countries: a systematic review","volume":"15","author":"Dimassi","year":"2025","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.cld.2026.01.009_bib33","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/ijerph18041647","article-title":"Barriers and facilitators associated with physical activity in the Middle East and North Africa region: a systematic overview","volume":"18","author":"Chaabane","year":"2021","journal-title":"Int J Environ Res Publ Health"},{"issue":"1","key":"10.1016\/j.cld.2026.01.009_bib34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12944-025-02710-7","article-title":"Culturally adapted hypocaloric diet improves hepatic steatosis, inflammatory and oxidative biomarkers in Egyptian MASLD patients: a single-arm interventional study","volume":"24","author":"Elhoseeny","year":"2025","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.cld.2026.01.009_bib35","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1186\/s12889-025-22631-5","article-title":"Stakeholder perspectives on surveillance of physical activity and monitoring and evaluation of interventions in Saudi Arabia","volume":"25","author":"Al-Hazzaa","year":"2025","journal-title":"BMC Public Health"},{"key":"10.1016\/j.cld.2026.01.009_bib36","doi-asserted-by":"crossref","DOI":"10.2196\/53651","article-title":"The use of mobile technologies to promote physical activity and reduce sedentary behaviors in the middle east and North Africa region: systematic review and meta-analysis","volume":"26","author":"Tong","year":"2024","journal-title":"J Med Internet Res"},{"issue":"6","key":"10.1016\/j.cld.2026.01.009_bib37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1123\/jpah.2022-0537","article-title":"Scoping review of population-based physical activity and sedentary behavior in Saudi Arabia","volume":"20","author":"Evenson","year":"2023","journal-title":"J Phys Activ Health"},{"issue":"11","key":"10.1016\/j.cld.2026.01.009_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.42750","article-title":"Cost-Effectiveness of MASH diagnosis and management approaches among those with type 2 diabetes","volume":"8","author":"Lazarus","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.cld.2026.01.009_bib39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2026.01.009_bib61","unstructured":"U.S. Food and Drug Administration. FDA Approves Treatment for Serious Liver Disease Known as \u2018MASH\u2019. Silver Spring, MD, USA: U.S. Food and Drug Administration; 15 August 2025. Available at: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash (Accessed 9 November 2025)."},{"issue":"18","key":"10.1016\/j.cld.2026.01.009_bib40","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2026.01.009_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/sjg.sjg_357_21","article-title":"The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"28","author":"Fouad","year":"2022","journal-title":"Saudi J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2026.01.009_bib44","doi-asserted-by":"crossref","first-page":"531","DOI":"10.15537\/smj.2019.6.23980","article-title":"Position statement on the diagnosis and management of non-alcoholic fatty liver disease","volume":"40","author":"Alswat","year":"2019","journal-title":"Saudi Med J"},{"issue":"10","key":"10.1016\/j.cld.2026.01.009_bib45","first-page":"791","article-title":"Mapping metabolic dysfunction-associated steatotic liver disease models of care across 17 Middle East and North Africa countries: insights into guidelines, infrastructure, and referral systems","volume":"13","author":"El-Kassas","year":"2025","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.01.009_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2468-1253(20)30213-2","article-title":"Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa","volume":"6","author":"Shiha","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2026.01.009_bib48","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/j.jhep.2024.01.033","article-title":"Joint position statement from the Middle East and North Africa and Sub-Saharan Africa on continuing to endorse the MAFLD definition","volume":"80","author":"Fouad","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2026.01.009_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70108","article-title":"Metabolic dysfunction-associated steatotic liver disease in the MENA region: setting a research and action priority agenda","volume":"45","author":"El-Kassas","year":"2025","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.cld.2026.01.009_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2024.101569","article-title":"Knowledge about metabolic dysfunction-associated steatotic liver disease among the medical professionals from countries in the MENA region","volume":"30","author":"Alqahtani","year":"2025","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.cld.2026.01.009_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1045739","article-title":"Healthcare system development in the Middle East and North Africa region: challenges, endeavors and prospective opportunities","volume":"10","author":"Katoue","year":"2022","journal-title":"Front Public Health"},{"issue":"8","key":"10.1016\/j.cld.2026.01.009_bib52","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3390\/pathogens13080681","article-title":"Hepatitis C elimination in Egypt: story of success","volume":"13","author":"Gomaa","year":"2024","journal-title":"Pathogens"},{"issue":"3","key":"10.1016\/j.cld.2026.01.009_bib55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4103\/sjg.sjg_431_24","article-title":"A bibliometric analysis of a decade\u2019s research on metabolic dysfunction-associated steatotic liver disease in the Arab world","volume":"31","author":"Alhazzani","year":"2025","journal-title":"Saudi J Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2026.01.009_bib56","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3390\/metabo12121240","article-title":"Molecular screening via sanger sequencing of the genetic variants in non-alcoholic fatty liver disease subjects in the Saudi Population: a hospital-based Study","volume":"12","author":"Alsaif","year":"2022","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.cld.2026.01.009_bib57","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70088","article-title":"Underrepresentation of Arabs in functional genetics studies: opportunities and obstacles for advancing biology and human health","volume":"45","author":"Pan","year":"2025","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.cld.2026.01.009_bib58","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s12072-021-10182-x","article-title":"Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait","volume":"15","author":"Sanai","year":"2021","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.cld.2026.01.009_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0317929","article-title":"Assessment of ChatGPT-generated medical Arabic responses for patients with metabolic dysfunction-associated steatotic liver disease","volume":"20","author":"Alqahtani","year":"2025","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cld.2026.01.009_bib60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s43066-020-00044-w","article-title":"Assessment of hepatic fibrosis and steatosis by vibration-controlled transient elastography and controlled attenuation parameter versus noninvasive assessment scores in patients with nonalcoholic fatty liver disease","volume":"10","author":"Mansour","year":"2020","journal-title":"Egypt Liver J"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:57:40Z","timestamp":1778878660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326126000097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1089326126000097"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.009","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic Dysfunction-Associated Steatohepatitis in the Middle East: Clinical Challenges and Strategies to Bridge the Gap","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}